After gaining experience from large population sequencing projects, there is a significant gap between the promise of genomics in Precision Medicine (PM) and the existing state of affairs. To fully exploit this potential, Public Healthcare (PH) must adopt procedures, regulations, and technology that are unfamiliar to them. The development needs to be improved by several historical procedures and regulatory hurdles. In the future, PM will include making genetic big data easily accessible at the point of treatment and implementing tools to govern its use effectively. Significant modifications need to be made in billing, payment, and monitoring to accomplish this goal. New systemic and technological structures must also be developed inside the healthcare sector. The responsibilities of clinical geneticists will expand to include overseeing PM systems. Genetic counselors will guide and assist PM by establishing and upholding PM structures. The trajectory of the research is now hindered by several impediments, resulting in avoidable fatalities. Revamping medical facilities to accommodate genomics has the potential to influence the treatment of patients significantly and enable the achievement of long-awaited advancements in PM.
Read full abstract